Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Kaufman, Howard L ^a   Kim Schulze, Seunghee ^a   Manson, Kelledy ^b   DeRaffele, Gail ^a   Mitcham, Josephine ^a   Seo, Kang Seok ^a   Kim, Dae Won ^a   Marshall, John ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MUCIN 1; RECOMBINANT B7 ANTIGEN CARCINOEMBRYONIC ANTIGEN INTERCELLULAR ADHESION MOLECULE 1 LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3 MUCIN 1 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; CA 15-3 ANTIGEN; CANCER ANTIBODY; CANCER VACCINE;

ADULT; AGED; ANOREXIA; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOWLPOX VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; MYALGIA; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; POXVIRUS; SURVIVAL TIME; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VOMITING; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; MIDDLE AGED; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTIBODIES, NEOPLASM; CA-15-3 ANTIGEN; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; T-LYMPHOCYTES; VACCINIA VIRUS;

EID: 38849160991     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-60     Document Type: Article

References (48)

1. American Cancer Society Cancer Facts & Figures 2006: Atlanta: American Cancer Society 2006 http://www.cancer.org Accessed May 8, 2006.
2. Li D Xie K Wolff R Abbruzzese JL Pancreatic cancer Lancet 2004, 363:1049-1057. 10.1016/S0140-6736(04)15841-8 15051286
3. Ko AH Dito E Schillinger B Venook AP Bergsland EK Tempero MA Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas J Clin Oncol 2006, 24:379-385. 10.1200/ JCO.2005.01.8267 16344320
4. Tempero M Alasadi R Behrman S Clinical practice guidelines in oncology. Pancreatic Adenocarcinoma National Comprehensive Cancer Network 2006 http://www.nccn.org
5. Laheru D Jaffee EM Immunotherapy for pancreatic cancer - science driving clinical progress Nat Rev Cancer 2005, 5:459-467. 10.1038/nrc1630 15905855
6. Tsang KY Palena C Gulley J Arlen P Schlom J A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1 Clin Cancer Res 2004, 10:2139-2149. 10.1158/1078-0432.CCR-1011-03 15041735
7. Finn OJ Jerome KR Henderson RA Pecher G Domenech N Magarian-Blander J Barratt-Boyes SM MUC-1 epithelial tumor mucin-based immunity and cancer vaccines Immunol Rev 1995, 145:61-89. 10.1111/j.1600-065X.1995.tb00077.x 7590831
8. Aarts WM Schlom J Hodge JW Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity Cancer Res 2002, 62:5770-5777. 12384537
9. Tsang KY Palena C Yokokawa J Arlen PM Gulley JL Mazzara GP Gritz L Gomez Yafal A Ogueta S Greenhalgh P Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules Clin Cancer Res 2005, 11:1597-1607. 10.1158/1078-0432.CCR-04-1609 15746065
10. Pantuck AJ van Ophoven A Gitlitz BJ Tso CL Acres B Squiban P Ross ME Belldegrun AS Figlin RA Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer J Immunother 2004, 27:240-253. 10.1097/00002371-200405000-00009 15076142
11. Bu D Domenech N Lewis J Taylor-Papadimitriou J Finn OJ Recombinant vaccinia mucin vector: In vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition J Immunother 1993, 14:127-135. 10.1097/ 00002371-199308000-00008
12. Balloul JM Acres RB Geist M Dott K Stefani L Schmitt D Drillien R Spehner D McKenzie I Xing PX Recombinant MUC 1 vaccinia virus: A potential vector for immunotherapy of breast cancer Cell Mol Biol (Noisy-le-grand) 1994, 40(Suppl 1):49-59. 7950862
13. Akagi J Nakagawa K Egami H Ogawa M Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus Cancer Immunol Immunother 1998, 47:21-31. 10.1007/s002620050500 9755875
14. Hodge JW McLaughlin JP Kantor JA Schlom J Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses Vaccine 1997, 15:759-768. 10.1016/S0264-410X(96)00238-1 9178479
15. Zhu MZ Marshall J Cole D Schlom J Tsang KY Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine Clin Cancer Res 2000, 6:24-33. 10656428
16. Kudo-Saito C Hodge JW Kwak H Kim-Schulze S Schlom J Kaufman HL 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines Vaccine 2006, 24:4975-4986. 1865095 16621183 10.1016/j.vaccine.2006.03.042
17. Croft M Dubey C Accessory molecule and costimulation requirements for CD4 T cell response Crit Rev Immunol 1997, 17:89-118. 9034725
18. Kaufman HL Cohen S Cheung K DeRaffele G Mitcham J Moroziewicz D Schlom J Hesdorffer C Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors Hum Gene Ther 2006, 17:239-244. 10.1089/hum.2006.17.239 16454657
19. Hodge JW Greiner JW Tsang KY Sabzevari H Kudo-Saito C Grosenbach DW Gulley JL Arlen PM Marshall JL Panicali D Schlom J Costimulatory molecules as adjuvants for immunotherapy Front Biosci 2006, 11:788-803. 10.2741/1837 16146771
20. Dipaola R Plante M Kaufman H Petrylak D Israeli R Lattime E Manson K Schuetz T A Phase I Trial of Pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in Patients with Prostate Cancer J Transl Med 2006, 4:1-5. 1360095 16390546 10.1186/1479-5876-4-1
21. Kaufman HL DeRaffele G Mitcham J Moroziewicz D Cohen SM Hurst-Wicker KS Cheung K Lee DS Divito J Voulo M Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma J Clin Invest 2005, 115:1903-1912. 1142116 15937544 10.1172/ JCI24624
22. Kaufman HL Wang W Manola J DiPaola RS Ko YJ Sweeney C Whiteside TL Schlom J Wilding G Weiner LM Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group J Clin Oncol 2004, 22:2122-2132. 10.1200/ JCO.2004.08.083 15169798
23. Shankar P Schlom J Hodge J Enhanced activation of rhesus T cells by vectors endcoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3) Vaccine 2002, 20:744-755. 10.1016/S0264-410X(01)00409-1
24. Hodge J Sabzevari H Yafal A Gritz L Lorenz M Schlom J A triad of costimulatory molecules synergize to amplify T-cell activation Cancer Res 1999, 59:5800-5807. 10582702
25. Hodge J Abrams S Schlom J Kantor J Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules Cancer Res 1994, 54:5552-5555. 7522961
26. Shankar P Schlom J Hodge JW Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3) Vaccine 2001, 20:744-755. 10.1016/S0264-410X(01)00409-1 11738738
27. Wang R Epstein J Baraceros FM Gorak EJ Charoenvit Y Carucci DJ Hedstrom RC Rahardjo N Gay T Hobart P Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine Proc Natl Acad Sci USA 2001, 98:10817-10822. 58557 11526203 10.1073/pnas.181123498
28. Sedegah M Jones TR Kaur M Hedstrom R Hobart P Tine JA Hoffman SL Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine Proc Natl Acad Sci USA 1998, 95:7648-7653. 22711 9636204 10.1073/pnas.95.13.7648
29. Hodge JW Poole DJ Aarts WM Gomez Yafal A Gritz L Schlom J Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses Cancer Res 2003, 63:7942-7949. 14633725
30. Santra S Sun Y Parvani JG Philippon V Wyand MS Manson K Gomez-Yafal A Mazzara G Panicali D Markham PD Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors J Virol 2007, 81:8563-8570. 10.1128/JVI.00744-07 17553898 1951337
31. Dranoff G Jaffee E Lazenby A Golumbek P Levitsky H Brose K Jackson V Hamada H Pardoll D Mulligan RC Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity Proc Natl Acad Sci USA 1993, 90:3539-3543. 46336 8097319 10.1073/ pnas.90.8.3539
32. Morrissey PJ Bressler L Park LS Alpert A Gillis S Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells J Immunol 1987, 139:1113-1119. 3038997
33. Conry RM Allen KO Lee S-w Moore SE Shaw DR LoBuglio AF Human Autoantibodies to Carcinoembryonic Antigen (CEA) Induced by a Vaccinia-CEA Vaccine Clin Cancer Res 2000, 6:34-41. 10656429
34. Manson K Dolan K Marshall J A novel non-HLA restricted cellular immune assay for monitoring patient response to targeted immunotherapeutics Proc Am Soc Clin Oncol 2006, 24(Suppl 18S):2567.
35. Eichner M Analysis of Historical Data Suggests Long-lasting Protective Effects of Smallpox Vaccination Am J Epidemiol 2003, 158:717-723. 10.1093/aje/kwg225 14561660
36. Slierendregt BL van Noort JT Bakas RM Otting N Jonker M Bontrop RE Evolutionary stability of transspecies major histocompatibility complex class II DRB lineages in humans and rhesus monkeys Hum Immunol 1992, 35:29-39. 10.1016/0198-8859(92)90092-2 1478892
37. Otting N Bontrop RE Evolution of the major histocompatibility complex DPA1 locus in primates Hum Immunol 1995, 42:184-187. 10.1016/ 0198-8859(94)00095-8 7744622
38. Geluk A Elferink DG Slierendregt BL van Meijgaarden KE de Vries RR Ottenhoff TH Bontrop RE Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates J Exp Med 1993, 177:979-987. 10.1084/jem.177.4.979 8459225
39. 't Hart BA Bauer J Brok HP Amor S Non-human primate models of experimental autoimmune encephalomyelitis: Variations on a theme J Neuroimmunol 2005, 168:1-12. 10.1016/j.jneuroim.2005.05.017 16023737
40. Marshall JL Hoyer RJ Toomey MA Faraguna K Chang P Richmond E Pedicano JE Gehan E Peck RA Arlen P Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses J Clin Oncol 2000, 18:3964-3973. 11099326
41. Chan A Lockhart D von Bernstorff W Spanjaard R Joo H-G Eberlein T Goedegebuure P Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation Int J Cancer 1999, 82:721-726. 10.1002/ (SICI)1097-0215(19990827)82:5<721::AID-IJC16>3.0.CO;2-N 10417771
42. Ungefroren H Voss M Bernstorff WV Schmid A Kremer B Kalthoff H Immunological Escape Mechanisms in Pancreatic Carcinoma Ann NY Acad Sci 1999, 880:243-251. 10.1111/j.1749-6632.1999.tb09529.x 10415870
43. Feng Y Wang D Yuan R Parker CM Farber DL Hadley GA CD103 Expression Is Required for Destruction of Pancreatic Islet Allografts by CD8+ T Cells J Exp Med 2002, 196:877-886. 10.1084/jem.20020178 12370250
44. Gaspar NJ Li L Kapoun AM Medicherla S Reddy M Li G O'Young G Quon D Henson M Damm DL Inhibition of Transforming Growth Factor beta Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness Mol Pharmacol 2007, 72:152-161. 10.1124/mol.106.029025 17400764
45. French JJ Cresswell J Wong W Seymour K Charnley RM Kirby J T cell adhesion and cytolysis of pancreatic cancer cells: A role for E-cadherin in immunotherapy? Br J Cancer 2002, 87:1034-1041. 10.1038/sj.bjc.6600597 12434297
46. Jaffee EM Hruban RH Biedrzycki B Laheru D Schepers K Sauter PR Goemann M Coleman J Grochow L Donehower RC Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation J Clin Oncol 2001, 19:145-156. 11134207
47. Ryschich E Notzel T Hinz U Autschbach F Ferguson J Simon I Weitz J Frohlich B Klar E Buchler MW Schmidt J Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma Clin Cancer Res 2005, 11:498-504. 15701833
48. Marshall JL Gulley JL Arlen PM Beetham PK Tsang K-Y Slack R Hodge JW Doren S Grosenbach DW Hwang J Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen-Expressing Carcinomas J Clin Oncol 2005, 23:720-731. 10.1200/ JCO.2005.10.206 15613691